Lv1
48 积分 2026-06-07 加入
Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
2天前
已完结
Chinese guidelines for diagnosis and treatment of neuromyelitis optica spectrum disorders (2025 edition)
20天前
已完结
The spectrum of neuromyelitis optica
21天前
已完结
Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4-IgG-positive neuromyelitis optica spectrum disorder during acute attacks
21天前
已完结
An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib
1个月前
已完结
Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database
1个月前
已完结
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
1个月前
已完结
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
1个月前
已完结
Chinese guidelines for diagnosis and treatment of neuromyelitis optica spectrum disorders (2025 edition)
1个月前
已完结
Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study
2个月前
已完结
皖公网安备34019202002308
